ArticleBMC pediatrics2026
Clinicopathologic patterns and treatment outcomes of pediatric classic hodgkin lymphoma in Ethiopian newly opened cancer treatment centers.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric Hodgkin lymphoma (PHL) is the most common lymphoreticular cancer in adolescents aged between 15-19 years. The survival of PHL is over 95% in developed countries with or without radiation therapy. Proper staging and risk stratification of PHL before initiation of treatment is fundamental for cure. Although outcomes for PHL in developed countries are excellent, survival in low-income countries remains lower. PHL is one of the WHO six indexed cancers with a target survival of >60% by 2030 globally. The aim of the study was to evaluate clinicopathologic characteristics and treatment outcomes of PHL at two treatment centers in Ethiopia.
methodRetrospective cohort study was conducted from January 1,2020 to December 29, 2024 at both Gondar and Jimma pediatric treatment centers. All children under 18 years of age were included in the study population. Data were extracted from each patient’s medical chart review and entered with Epi-info to be analyzed using SPSS version 26. Overall survival (OS) and event free survival (EFS) were calculated and analyzed using Kaplan-Meier estimates. P-value less than 0.05 was considered statistically significant.
resultsThe study included 70 pediatric HL patients. The median age was 8.5 years (range: 4-18 years) and 77.1% of patients were males. Cervical lymphadenopathy was the commonest clinical presentation. Nodular sclerosis was the commonest histology subtype (34.3%) followed by mixed cellularity while 27% had uncategorized histology. Overall, 54.3% of patients had localized (stage I and II) and 45.7% of patients had advanced disease (stage III and IV) at initial staging. Adriamycin, Bleomycin, Vincristine, Etoposide, Prednisolone and Cyclophosphamide (ABVE-PC) was the commonest chemotherapy regimen used in our cohort (61.4%). Only 10% (7) of patients received radiation therapy all from the intermediate to high-risk group. In our study, the 3-year EFS and OS rate of pediatric HL was 85.7% and 98.6% accounting abandonment as censored. Treatment abandonment remains the challenge for cure in our cohort accounting about 31% to be censored.
conclusionsOur study showed that there was a trend towards earlier age at diagnosis of pediatric HL consistent with data from other developing countries. The treatment outcomes were good enough for newly opened centers in low-income countries with almost omission of radiotherapy, but treatment abandonment remains the challenge for cure as well affects the survival analysis in our cohorts. The treatment protocols used in this study surpassed the WHO indexed pediatric cancer survival target by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.